Navigation Links
PTC Therapeutics Reports Third Quarter 2013 Financial and Corporate Results

SOUTH PLAINFIELD, N.J., Nov. 14, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes, today announced financial and corporate results for the quarter ended September 30, 2013.

(Logo: )

"2013 has thus far been an exciting year for us. PTC was founded based upon a strong scientific platform focused on RNA biology with the goal of bringing new therapies to patients with rare disorders and we have made tremendous progress this year towards realizing that goal," said Stuart Peltz, PhD, Chief Executive Officer, PTC Therapeutics, Inc. "We initiated our nonsense mutation Duchenne muscular dystrophy confirmatory Phase 3 clinical trial, which was informed by our previous clinical results that defined the natural history of ambulation in DMD patients as measured by the six-minute walk test.  These natural history results have been corroborated by subsequent studies, giving us a high degree of confidence that our ongoing confirmatory study is both well designed and well powered to demonstrate the efficacy of ataluren.  In addition, a  development candidate was selected  in  our spinal muscular atrophy (SMA) program in  collaboration with Roche and the SMA Foundation.  This development candidate was originally developed using PTC's Alternative Splicing platform, which we are also deploying against other medically important targets."

"As we look ahead to 2014, we are well positioned to execute on our strategy. This includes completing enrollment in our nonsense mutation Duchenne muscular dystrophy confirmatory Phase 3 clinical trial and the initiation of our Phase 3 confirmatory trial in nonsense mutation cystic fibrosis. We also look forward to advancement of our other programs highlighted in our R&D day."

Corporate Highlights:

  • Publications in Muscle and Nerve validating six-minute walk test and describing ambulatory natural history in DMD patients: In August 2013, data published in two manuscripts in the medical journal Muscle & Nerve demonstrated the clinical meaningfulness of the six-minute walk test as a primary endpoint to measure disease progression and walking ability in ambulatory Duchenne muscular dystrophy trials.  The natural history data utilized for the analysis was obtained from PTC's Phase 2b trial of ataluren in 174 patients, the first registration–directed, placebo-controlled, multi-national study of a new chemical entity for DMD.
  • Presentations at multiple scientific conferences:  During the quarter, PTC presented at multiple scientific conferences including the European Pediatric Neurology Society Congress (EPNS), where PTC hosted a symposium titled "New perspectives in the management of Duchenne muscular dystrophy," the World Muscle Society Congress (WMS) and the North American Cystic Fibrosis Conference (NACFC). 
  • Chosen to join the Russell 2000 Index: On September 30th, PTC was added to the Russell 2000 Index.  The Russell 2000® Index, a subset of the Russell 3000® Index, measures the performance of the small-cap segment of the U.S. equity market.
  • Hosted first R&D Day: On October 25th, PTC hosted its first R&D day in New York City where PTC's senior management and research teams presented in-depth reviews of the company's scientific platforms and R&D programs.
  • Confirmatory Phase 3 Trial in nmDMD on track: In April 2013, PTC initiated a confirmatory Phase 3 clinical trial evaluating our investigational new drug ataluren as a potential treatment for patients with nonsense mutation Duchenne muscular dystrophy (nmDMD). The study is on-track to complete enrollment by mid-2014. The Phase 3 study is expected to be conducted at 53 clinical sites across 18 countries.
  • EMA regulatory process progressing: Following the October 2012 submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for conditional approval of ataluren in nmDMD, the regulatory process continues to progress.  The Committee for Medicinal Products for Human Use (CHMP) has recently notified us that it intends to convene a Scientific Advisory Group (SAG) meeting as part of the regulatory review process.  The SAG meeting may shift the timing of a final opinion from the CHMP on the conditional approval of ataluren in nmDMD from the last quarter of 2013 to the first quarter of 2014.  To manage our regulatory priorities, PTC also plans to delay the filing of an MAA for conditional approval of ataluren in nonsense mutation cystic fibrosis (nmCF) until the first quarter of 2014.
  • Third Quarter 2013 Financial Highlights:

  • Cash, cash equivalents, and marketable securities totaled $157.2 million at September 30, 2013 compared to $2.7 million at December 31, 2012.  The increase was primarily a result of receiving net proceeds of $60.8 million from PTC's equity private placement and $131.6 million from PTC's initial public offering in the first half of 2013 combined with a $10 million milestone achieved in the third quarter of 2013 from Roche for the selection of a development candidate in our SMA collaboration.
  • Revenue from grants and collaborations was $16.3 million for the third quarter of 2013, compared to $7.2 million for the same period in 2012.  The increase was primarily the result of the achievement of a $10 million milestone in our Roche collaboration. Collaboration revenue includes deferred revenue from payments received in previous periods as well as payments received and recognized during the respective periods. 
  • Total operating expenses were $20.6 million for the third quarter of 2013, including $2.6 million in stock based compensation expense, compared to $14.3 million for the same period in 2012, including $0.5 million in stock based compensation expense.  The increase was primarily due to higher research and development expenses related to the initiation of the Phase 3 clinical trial of ataluren for the treatment of nmDMD, as well as higher general and administrative expenses related to public company expenses and pre-commercial activities. 
  • Net loss for the third quarter of 2013 was $4.4 million compared to a net loss of $7.3 million for the same period in 2012.
  • Shares issued and outstanding as of September 30, 2013 were 24.9 million, which includes 1.1 million of unvested restricted stock.
  • Today's Conference Call and Webcast Reminder
    The PTC management team will host a conference call to discuss the company's financial results and recent and upcoming developments today, Thursday, November 14, 2013, at 8:00 a.m. ET. The call can be accessed by dialing 877-303-9216 (domestic) or 973-935-8152 (international) five minutes prior to the start of the call and providing the passcode 24942756.

    The live, listen-only webcast of the conference call can also be accessed by visiting the "Investors Relations" section of the company's website at A replay of the webcast will be archived on the PTC website for 30 days following the call.

    About PTC Therapeutics, Inc.
    PTC Therapeutics is biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and form the basis for collaborations with leading biopharmaceutical companies. For more information on the company, please visit our website

    Forward Looking Statements
    Any statements in this press release about future expectations, plans and prospects for PTC, the development of and potential market for PTC's product candidates, our Phase 3 clinical trials for ataluren in nmDMD and nmCF, our collaboration in SMA with Roche and the SMA Foundation, our current and planned regulatory filings with EMA, our earlier stage programs,  and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan" "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from those expressed or implied by these forward-looking statements. Such risks and uncertainties include, among others, those related to the initiation and conduct of clinical trials, availability of data from clinical trials, expectations for regulatory approvals, our scientific approach and general development progress, the availability or commercial potential of our product candidates and other factors discussed in the "Risk Factors" in the most recent Quarterly Report, which is on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent PTC's views only as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, the Company specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing PTC's views as of any date subsequent to the date of this press release.

     PTC Therapeutics, Inc.Statements of Operations(In thousands, except per share data)Three Months EndedNine Months EndedSeptember 30,September 30,2012201320122013Revenues:  Collaboration revenue

    $6,043$15,455$22,861$27,395  Grant revenue

    1,1528344,4452,890Total revenues and non-cash cancellation revenue

    7,19516,28927,30630,285Operating expenses:  Research and development (1)

    10,46613,88636,68939,855  General and administrative (1)

    3,7846,67911,39117,735Total operating expenses

    14,25020,56548,08057,590Loss from operations

    (7,055)(4,276)(20,774)(27,305)Interest (expense) income, net

    (247)27(1,007)(6,250)Loss on extinguishment of debt

    —(130)—(130)Other income (expense), net

    5(37)1,818(3)Net loss

    (7,297)(4,416)(19,963)(33,688)Deemed dividend

    ———(18,249)Gain on exchange of convertible preferred stock inconnection with recapitalization

    ——159,9543,391Less beneficial conversion charge

    ——(378)—Net (loss) income attributable to common stockholders

    ($7,297)($4,416)$139,613($48,546)Weighted-average shares outstanding (in shares):Basic


    4,54523,803,28213,5938,995,167Net (loss) income per share applicable to common stockholders - basic (in dollars per share)

    ($1,605.53)($0.19)$182.41($5.40)Net (loss) income per share applicable to common stockholders - diluted (in dollars per share)

    ($1,605.53)($0.19)$39.41($5.40)(1) Non-cash share-based compensation expenseincluded in operating expenses are as follows:Research and development

    $193$677$654$1,378General and administrative

    3271,9631,1623,764Total share-based compensation expense



     PTC Therapeutics, Inc.Summary Balance Sheet(In thousands, except share amounts)December 31, September 30,20122013Cash, cash equivalents and marketable securities

    $2,726$157,227Total assets$13,072$167,244Total debt

    4,88384Total deferred revenue

    17,4323,631Total liabilities$31,889$16,212Total stockholders' (deficit) equity (4,526 and 23,803,282 common shares issued and outstanding at December 31, 2012 and September 30, 2013, respectively)

    (99,641)151,032Total liabilities, convertible preferred stocks and stockholders' (deficit) equity$13,072$167,244 



    SOURCE PTC Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Aratana Therapeutics Reports Third Quarter 2013 Financial Results
    2. Levi & Korsinsky, LLP Launches Investigation of SAREPTA THERAPEUTICS, INC. for Possible Violations of Federal Securities Laws
    3. Argos Therapeutics to Present at the Elsevier Therapeutic Area Partnerships Meeting
    4. Mirati Therapeutics Reports Third Quarter 2013 Financial Results
    5. Sorrento Therapeutics Adopts Stockholder Rights Plan
    6. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
    7. Shield Therapeutics Files Investigational New Drug Application for ST10 for the Treatment of Iron Deficiency in Chronic Kidney Disease
    8. Cara Therapeutics Files Registration Statement for Proposed Initial Public Offering
    9. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
    10. Echo Therapeutics Announces Third Quarter 2013 Financial Results
    11. Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
    Post Your Comments:
    (Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
    (Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
    (Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
    Breaking Medicine Technology:
    (Date:4/28/2017)... ... 2017 , ... Ushio America proudly introduces the new ... solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts so ... lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s easy ...
    (Date:4/28/2017)... Md. (PRWEB) , ... April 28, 2017 , ... ... Association of America (UCAOA) and College of Urgent Care Medicine will host industry ... workshops, sessions and speakers will help those in the industry adapt to the ...
    (Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in ... activity and sleep monitoring solutions for the global scientific community. The company’s new ...
    (Date:4/28/2017)... ... 28, 2017 , ... Rob Lowe is a popular actor that has been ... to an educational purpose as the host of the “Informed” series. The program focuses ... recent episode, the series focuses on thyroid cancer. , Although thyroid cancer is an ...
    (Date:4/27/2017)... ... April 27, 2017 , ... Healthcare companies are trying ... will rapidly reject an outdated healthcare executive resume. , “If you’re a healthcare executive ... executive resume and wondering if it’s as ready as you are for a new ...
    Breaking Medicine News(10 mins):